Normobaric oxygen may correct chronic cerebral ischemia-mediated EEG anomalies

Jia-Yue Ding1,2 | Yu Liu3 | Gary-B. Rajah4 | Zhi-Ying Chen1,5,6 | Shi-Yong Zhang7 | Yu-Chuan Ding6,8 | Xun-Ming Ji5,6,9 | Ran Meng1,5,6

Abstract

Aims: To explore the safety and efficacy of normobaric oxygen (NBO) on correcting chronic cerebral ischemia (CCI) and related EEG anomalies.

Methods: This prospective randomized trial (NCT03745092) enrolled 50 cases of CCI patients, which were divided into NBO (8 L/min of oxygen supplement) group and control group (room air) randomly, and also enrolled 21 healthy volunteers. Two times of 30-min EEG recordings with the interval of 45 min of NBO or room air were analyzed quantitatively.

Results: The CCI-mediated EEG presented with two patterns of electrical activities: high-power oscillations (high-power EEG, n = 26) and paroxysmal slow activities under the normal-power background (normal-power EEG, n = 24). The fronto-central absolute power (AP) of the beta, alpha, theta, and delta in the high-power EEG was higher than that in healthy EEG (p < 0.05). The fronto-central theta/alpha, delta/alpha and (delta + theta)/(alpha + beta) ratios in the normal-power EEG were higher than those in healthy EEG (p < 0.05). The high-power EEG in NBO group had higher fronto-central AP reduction rates than those in control group (p < 0.05). NBO remarkably reduced the fronto-central theta/alpha, delta/alpha and (delta + theta)/(alpha + beta) ratios in the normal-power EEG (p < 0.05).

Conclusions: NBO rapidly ameliorates CCI-mediated EEG anomalies, including attenuation of the abnormal high-power oscillations and the paroxysmal slow activities associated with CCI.

KEYWORDS
brain dysfunction, chronic ischemia, electrophysiology, oxygen
INTRODUCTION

As we all know, the chronic cerebral ischemia (CCI) is very popular and intractable condition in clinical setting. Patients with CCI often complain about long-term non-specific symptoms, such as headache, dizziness, memory decline, and insomnia, which seriously affected their quality of life. The predominant etiology of CCI is atherosclerotic stenosis, especially intracranial arterial stenosis (ICAS) in Chinese populations, which may be responsible for 33%–50% of ischemic stroke events and more than 50% transient ischemic attack (TIA). The latest epidemiological statistics reported that CCI carries a high incidence in elderly people, occurring in more than two-thirds of individuals older than 65 years of age. Despite statins and antiplatelet use can largely block stroke occurrence and recurrence induced by CCI, to date there are no effective strategies aimed at correcting CCI-mediated brain dysfunctions.

Normobaric oxygen (NBO), supplied by nasal cannula or face-mask with one atmosphere pressure (1 ATA = 101.325 kPa), has been utilized as an adjuvant therapy for correcting various diseases. NBO could ameliorate hypoxia of brain tissue, correct brain dysfunction rapidly, and finally improve clinical outcomes. However, to our knowledge, few studies about NBO on correcting CCI-related brain dysfunctions are reported at present. EEG can comprehensively reflect the changes of brain function induced by cerebral ischemia and hypoxia; herein, we aimed to evaluate the efficacy of NBO on correcting CCI-mediated brain dysfunctions by real-time quantitative EEG analysis.

METHODS

2.1 Study design and participants

This is a proof-of-concept, assessor-blinded, randomized controlled clinical trial registered on ClinicalTrials.gov (http://www.clinicaltrials.gov; Unique identifier: NCT03745092) and has been approved by the Institutional Ethics Committee of Xuanwu Hospital, Capital Medical University (Beijing, China) in accordance with the guidelines of the 1964 Declaration of Helsinki. Informed consent was obtained from all individuals prior to their enrollment. As the EEG features for CCI are currently not clearly defined, this study analyzed the abnormal EEG oscillations in CCI (Part I) for the first time, and explored the efficacy of NBO on correcting CCI-mediated brain dysfunctions by real-time quantitative EEG analysis.

2.2 Study procedures

In Part I, all of the enrolled patients was labeled as the CCI group and underwent 30-min EEG recordings twice. During the interval of the two times of EEG recordings, the patients were randomly assigned to receive NBO (8 L/min of oxygen supplement for 45 min via simple mask) or room air (resting like lying, sitting, or walking at room air for 45 min without any other specific interventions) randomly according to the random number, and these two arms were labeled as NBO group and control group, respectively in Part II. All of the healthy volunteers was also incorporated into this study. This population was confirmed to harbor no cerebral vascular diseases and had no arteriolar atherosclerosis-related risk factors (such as hypertension, diabetes, dyslipidemia, etc.).

From December 2018 through December 2019, patients with imaging confirmed CCI induced by ICAS and/or extracranial carotid arterial stenosis (ECAS) at Xuanwu Hospital, Capital Medical University, were enrolled in this study and randomly entered into NBO group or control group according to the random number. The diagnosis of ICAS and ECAS was confirmed by magnetic resonance angiography (MRA) and/or computed tomographic angiography (CTA). Perfusion weighted imaging (PWI) scan was used to confirm the status of CCI, and the parameter used in this study was mainly the time-to-peak time (TTP). Prolonged TTP in territory of stenosis arteries was considered as hypo-perfusion. All of the enrolled patients matched the following criteria.

Inclusion criteria: (1) age from 18 to 80 years; (2) ICAS and/or ECAS confirmed by imaging, with prolonged TTP; (3) NIHSS ≤3 and mRS ≤2; (4) signed the informed consent.

Exclusion criteria: (1) brain infarction occurrence within two months; (2) intracranial arterial aneurysm, dissection or malformation; (3) history of cerebral hemorrhage or subarachnoid hemorrhage; (4) brain trauma; (5) other brain injury or disorders; (6) austere diseases such as cancer, heart failure, and respiratory failures; (7) respiratory diseases; (8) severe liver and kidney dysfunction; (9) poor compliance.

In order to elucidate EEG features of CCI, a cohort of healthy volunteers was also incorporated into this study. This population was confirmed to harbor no cerebral vascular diseases and had no arteriolar atherosclerosis-related risk factors (such as hypertension, diabetes, dyslipidemia, etc.).

...
automatically using the BSS algorithm (sobi) that was implemented into EEGLAB software packages.

2.3 Outcomes

The absolute power (AP, with unit uV²) was computed using Fast Fourier Transform (FFT) for each electrode over the delta (1–4 Hz), theta (4–8 Hz), alpha (8–13 Hz), and beta (13–20 Hz) frequency bands, and the relative power (RP) was a ratio of the frequency band of interest power to the total power across the 1–20 Hz range. The power spectral density (PSD) for each channel was estimated via Welch’s procedure with a 2-s Hamming window length. The spectral power over the fronto-central electrodes (F3, F4, Fz, C3, C4, and Cz), which were with less occipital alpha oscillation impact, was used to reflect the actual frequency activities in the forehead. The spectral power over the global electrodes (21 channels) was also presented as a reference. The fronto-central alpha AP >1000 uV² and ≤1000 uV²
were categorized as the high-power EEG and the normal-power EEG. Utilizing python software, the EEG wavelet entropy (with unit nat) was calculated via nonlinear dynamics method in order to evaluate the degree of brain injury. Power ratio index (PRI) was defined as AP ratios of theta/alpha (TAR), delta/alpha (DAR), (delta + theta)/ (alpha + beta) (DTABR), and fronto-central alpha/occipital alpha/3 (FOAR) in this study. For Part II, each frequency-band AP and RP reduction rates were calculated as a ratio of the (pre- minus post- intervention) band power to pre-intervention band power.

2.4 | Statistical analysis

R software (http://www.r-project.org) was used for analysis in this study. Kolmogorov-Smirnov test was used to assess the data distribution. Continuous data were expressed as mean ± standard deviation (SD) or median (interquartile range, IQR). Dataset following a Gaussian distribution was analyzed with Student’s t test; otherwise analyzed with Mann-Whitney U test. As for multiple comparisons among groups, LSD method was used to remove the statistical bias from repeated measure. The comparisons between the prior and post-intervention parameters were performed with paired samples t test; otherwise paired samples Wilcoxon test. Categorical data were presented as numerical (percentage) and preceded by chi-square test. Multiple analyses using a linear regression model were used to rule out the confounding effect of other covariates that may affect the EEG measures. p-value < 0.05 was indicative of statistical significance.

3 | RESULTS

3.1 | Part I: the EEG anomalies in patients with CCI

A total of 50 eligible patients confirmed as CCI by perfusion imaging and 21 healthy volunteers were recruited in this study consecutively. Two senior doctors with extensive EEG experience finished the initial visual evaluations of the EEG maps and found that CCI patients had abnormal high voltage and amplitude waveforms over the forehead electrodes, and others had paroxysmal slow activities under the normal voltage background. Whereby, according to the fronto-central alpha AP >1000 μV^2 and ≤1000 μV^2, the patients were considered to harbor high-power EEG (26 cases) and the normal-power EEG (24 cases). Baseline characteristics among the cohorts with the high-power EEG, the normal-power EEG, and the healthy EEG were similar, except for age and male percentage were lower in the healthy volunteers (Table 1).

3.1.1 | Abnormal AP and RP

Both the raw EEG and the PSD curves unraveled the remarkable differences among the high-power EEG (n = 26), the normal-power EEG (n = 24), and the healthy EEG (n = 21) (Figure S1). For the fronto-central electrodes, the beta, alpha, theta, and delta AP in the high-power EEG were substantially higher than those in the normal-power EEG (p = 0.001, adjusted p < 0.001; p < 0.001, adjusted p < 0.001; p = 0.001, adjusted p = 0.004; p = 0.069, adjusted p = 0.044) and the healthy EEG (p = 0.001, adjusted p = 0.128; p < 0.001, adjusted p = 0.001; p < 0.001, adjusted p = 0.005; p = 0.001, adjusted p = 0.001). However, no difference was observed between the normal-power EEG and the healthy EEG (all p>0.05). The alpha RP in the high-power EEG was also higher than that in the normal-power EEG (p < 0.001, adjusted p < 0.001) and the healthy EEG (p < 0.001, adjusted p = 0.053). In the normal-power EEG, the theta and delta RP were significantly higher than those in the high-power EEG (p = 0.010, adjusted p = 0.020; p < 0.001, adjusted p < 0.001) and the healthy EEG (p = 0.041, adjusted p = 0.253; p = 0.022, adjusted p = 0.064). However, the alpha RP was soundly lower than those in the high-power EEG (p<0.001, adjusted p<0.001) and the healthy EEG (p = 0.009, adjusted p = 0.270). The differences in the global beta, alpha, theta, and delta AP and RP among the three types of EEG were similar to those over the fronto-central electrodes aforementioned. Details were shown in Figure 2, and Tables S1-S3.

3.1.2 | Abnormal PRI

The fronto-central TAR, DAR, and DTABR in the normal-power EEG were substantially higher than those in both the high-power EEG (p<0.001, adjusted p<0.001; p<0.001, adjusted p = 0.001; p<0.001, adjusted p = 0.001) and the healthy EEG (p = 0.004, adjusted p = 0.043; p = 0.023, adjusted p = 0.034; p = 0.011, adjusted p = 0.016), but no difference could be found between the high-power and the healthy EEG (all p>0.05, adjusted p>0.05). Meanwhile, the FOAR in the high-power EEG was much higher than that in the normal-power (p = 0.021, adjusted p = 0.065) and the healthy EEG (p = 0.003, adjusted p = 0.375). Furthermore, the global TAR, DAR, and DTABR in the normal-power EEG were also greater than those in the high-power EEG and the healthy EEG (all p<0.05, all adjusted p<0.05). Details were displayed in Figure 2 and Table S4.

3.1.3 | Abnormal wavelet entropy

The fronto-central wavelet entropy in the CCI patients was statistically lower than that in the healthy volunteers (p = 0.055, adjusted p = 0.008). As for the CCI patients with high-power EEG, the fronto-central wavelet entropy was lower than that in both the CCI patients with normal-power EEG (p = 0.001, adjusted p = 0.013) and the volunteers with healthy EEG (p = 0.001, adjusted p = 0.002), whereas the difference of the fronto-central wavelet entropy between the CCI patients with normal-power EEG and the volunteers with healthy EEG did not reach statistical significance (p = 0.859, adjusted p = 0.074). At the global areas of the brain, the statistical results were almost the same as the results mentioned above (see Table S5).
Forty-nine out of 50 CCI patients finished the second time of 30-minute EEG recording (one patient was rejected from final analysis due to the unavoidable artifact at the second time of EEG recording), in which 26 patients randomly entered into NBO group and all of them finished 45 minutes of NBO intervention during the interval of the two times of EEG recordings (baseline EEG recording

### TABLE 1 The clinical features of enrolled populations

| Demographics | High-power EEG | Normal-power EEG | Health EEG |
|--------------|----------------|------------------|------------|
| Num.         | 26             | 24               | 21         |
| Age, yr      | 56.31±9.64     | 60.46±7.70       | 30.57±9.31 |
| Male/female  | 21/5           | 16/8             | 4/17       |

| Comorbid disease, n (%) | High-power EEG | Normal-power EEG | Health EEG |
|-------------------------|----------------|------------------|------------|
| Hypertension            | 16 (61.5)      | 15 (62.5)        | NA         |
| Diabetes                | 13 (50.0)      | 8 (33.3)         | NA         |
| Dyslipidemia            | 22 (84.6)      | 18 (75.0)        | NA         |
| Hyperuricemia           | 9 (34.6)       | 8 (33.3)         | NA         |
| Atrial fibrillation     | 2 (7.7)        | 1 (4.2)          | NA         |
| Coronary heart disease  | 8 (30.8)       | 3 (12.5)         | NA         |

| Clinical features | High-power EEG | Normal-power EEG | Health EEG |
|-------------------|----------------|------------------|------------|
| Non-focal neurological disorder, n (%) | 21 (80.8) | 22 (91.7) | NA |
| Focal neurological disorder, n (%) | 3 (11.5) | 5 (20.8) | NA |
| NIHSS              | 1 (0.2)       | 1 (0.25, 2)     | NA         |
| mRS                | 0 (0.1)       | 0 (0.0)         | NA         |

| Imaging presentations, n (%) | High-power EEG | Normal-power EEG | Health EEG |
|-----------------------------|----------------|------------------|------------|
| Unilateral anterior circulation stenosis | 8 (30.8) | 7 (29.2) | NA |
| Bilateral anterior circulation stenosis | 16 (61.5) | 16 (66.7) | NA |
| MCA stenosis                | 23 (88.5)     | 21 (87.5)       | NA         |
| ACA stenosis                | 4 (15.4)      | 6 (25.0)        | NA         |
| PCA stenosis                | 7 (26.9)      | 9 (37.5)        | NA         |
| VA stenosis                 | 7 (26.9)      | 5 (20.8)        | NA         |
| BA stenosis                 | 5 (19.2)      | 4 (16.7)        | NA         |
| ICA stenosis                | 10 (38.5)     | 9 (37.5)        | NA         |
| Brain infarction            | 1 (3.8)       | 1 (4.2)         | NA         |
| Scheltens scales, median (IQR) | 4 (2, 6) | 7 (3, 12.25) | NA |

Abbreviation: NA, not available.

### FIGURE 2 Differences in the spectral power and PRI among the high-power EEG, normal-power EEG, and healthy EEG. Mean±SD, *<0.05, **<0.01

#### 3.2 Part II: the effect of NBO on EEG anomalies

Forty-nine out of 50 CCI patients finished the second time of 30-minute EEG recording (one patient was rejected from final analysis due to the unavoidable artifact at the second time of EEG recording), in which 26 patients randomly entered into NBO group and all of them finished 45 minutes of NBO intervention during the interval of the two times of EEG recordings (baseline EEG recording
showed that 15 cases of them presented as high-power EEG and another 11 cases were normal-power EEG; 23 patients randomly entered into control group underwent 45-minute resting in room air during the interval of the two times of EEG recordings (baseline EEG recording revealed that 10 cases of them presented as high-power EEG and other 13 cases were normal-power EEG). These two arms were well-matched in all baseline characteristics except for the ages. Details were illustrated in Table 2 and Table S6.

### 3.2.1 AP and RP correction

Among the CCI patients with high-power EEG in NBO group (baseline vs. post- NBO), NBO reduced the fronto-central AP of the four frequency bands, but only the changes of the alpha AP reached significance ($p = 0.042$). However, the fronto-central RP of the each frequency band did not change after NBO (all $p>0.05$). As for the patients with high-power EEG in control group (baseline vs. post-resting in room air), the fronto-central beta AP ($p = 0.01$) and the theta RP ($p = 0.018$) increased significantly; both the AP and the RP of the other frequency bands were not changed (all $p>0.05$). In addition, the global AP of the four frequency bands tended to be reduced by NBO (all $p>0.05$) and the global theta RP was increased in control group ($p = 0.001$). An example of raw EEG and PSD was demonstrated in Figure S2.

Among the CCI patients with normal-power EEG in NBO group (Baseline vs. post-NBO), the fronto-central beta AP ($p = 0.028$), theta AP ($p = 0.035$), and delta RP ($p = 0.030$) declined, and alpha RP ($p = 0.010$) elevated after NBO. As for the patients with the normal-power EEG in control group (Baseline vs. post-resting in room air), only the fronto-central alpha AP ($p = 0.028$) increased mildly. As for the global areas in the brain, the changes of neither the AP nor the RP of the frequency bands in both NBO and control groups showed no statistical significance (all $p>0.05$). Details were displayed in Figure 3 and Table S7.

### 3.2.2 PRI correction

Among the CCI patients with high-power EEG in NBO group (baseline vs. post-NBO), the changes of all the fronto-central TAR, DAR, and DTABR did not reach statistical significance, while the FOAR decreased obviously after NBO use ($p = 0.041$). As for control group (baseline vs. post-resting in room air), only the TAR elevated after resting in room air ($p = 0.017$). Notably, the reduction rates of the fronto-central beta AP, alpha AP, theta AP, and delta AP in NBO group were substantially higher than that in control group ($p = 0.002$, $p = 0.047$, $p = 0.016$, and $p = 0.012$, respectively). However, all of the reduction rates of the frequency-band RP between NBO and control groups did not reach statistical significance (all $p>0.05$). Additionally, the global TAR, DAR, and DTABR did not change profoundly in NBO group; in contrast, the TAR in control group elevated substantially ($p = 0.005$). The reduction rates of the global theta AP and RP in NBO group were significantly higher than those in control group ($p = 0.026$; $p = 0.012$).

For the CCI patients with normal-power EEG (Baseline vs. post-NBO), NBO significantly reduced the fronto-central TAR ($p = 0.021$), DAR ($p = 0.021$), and DTABR ($p = 0.021$), whereas all these indexes showed no remarkable changes in control group (baseline vs. post-resting in room air). The reduction rates of the beta AP ($p = 0.012$) and theta AP ($p = 0.034$) in NBO group were higher than those in control group. However, the reduction rates of RP between the two groups did not reach statistical significance ($p>0.05$). Moreover, the changes of the data of global TAR, DAR, DTABR, and FOAR in both NBO group and control did not reach statistical significance (all $p>0.05$). The reducing rates of global beta AP ($p = 0.026$) and theta AP ($p = 0.034$) in NBO group

### Table 2 Baseline characteristics of treatment groups

|                          | NBO group | Control group | p-value |
|--------------------------|-----------|---------------|---------|
| **Demographics**         |           |               |         |
| Num.                     | 26        | 23            | NA      |
| Age, yr                  | 60.5±8.3  | 55.0±8.4      | 0.025   |
| Male/female              | 18/8      | 19/4          | 0.277   |
| **Comorbid disease, n (%)** |       |               |         |
| Hypertension             | 14 (53.8) | 16 (69.6)     | 0.260   |
| Diabetes                 | 11 (42.3) | 10 (43.5)     | 0.934   |
| Dyslipidemia             | 22 (84.6) | 17 (73.9)     | 0.567   |
| Hyperuricemia            | 10 (38.5) | 7 (30.4)      | 0.556   |
| Atrial fibrillation      | 2 (7.7)   | 1 (4.3)       | 1.000   |
| Coronary heart disease   | 7 (26.9)  | 4 (17.4)      | 0.425   |
| **Clinical features**    |           |               |         |
| Non-focal neurological disorder, n (%) | 22 (84.6) | 20 (87.0)     | 1.000   |
| Focal neurological disorder, n (%) | 5 (19.2)  | 3 (13.0)      | 0.843   |
| NIHSS                    | 1 (0.2)   | 1 (1.2)       | 0.435   |
| mRS                      | 0 (0, 1)  | 0 (0, 0)      | 0.399   |
| **Imaging presentations, n (%)** |         |               |         |
| Unilateral anterior circulation stenosis | 5 (19.2)  | 9 (39.1)      | 0.124   |
| Bilateral anterior circulation stenosis | 21 (80.8) | 11 (47.8)     | 0.016   |
| MCA stenosis             | 24 (92.3) | 19 (82.6)     | 0.550   |
| ACA stenosis             | 7 (26.9)  | 3 (13.0)      | 0.396   |
| PCA stenosis             | 11 (42.3) | 5 (21.7)      | 0.125   |
| VA stenosis              | 7 (26.9)  | 5 (21.7)      | 0.674   |
| BA stenosis              | 5 (19.2)  | 4 (17.4)      | >0.999  |
| ICA stenosis             | 12 (46.2) | 7 (30.4)      | 0.260   |
| Brain infarction         | 1 (3.8)   | 1 (4.3)       | 1.000   |
| Scheltens scales, median (IQR) | 5 (3, 9.5) | 3 (2.8)       | 0.347   |

Abbreviation: NA, not available.
were greater than that in control group. Details can be found in Figure 4 and Table S8.

3.2.3 Wavelet entropy change

As for both the high-power EEG and the normal-power EEG, the differences of the fronto-central entropy (pre-minus post-intervention) between NBO group and control group did not reach statistical significance; the global entropy between the two groups showed no statistical significance as well (all \( p > 0.05 \)). Details were shown in Table S9.

3.2.4 The follow-up EEG analysis

A total of seven patients who underwent NBO 45min/3 times daily for a median 4 months (range: 3–6 months) finished the follow-up EEG recordings. Five out of the 7 patients were with the high-power EEG, and 2 patients were with the normal-power EEG at their
baseline EEG maps. No patient complained of uncomfortable and adverse events onset during the period of continuous NBO intervention, each of them had a good compliance. As for the high-power EEG, the fronto-central alpha AP and RP were significantly reduced and the beta RP tended to be increased. All of above can be seen in Table S10.

4 | DISCUSSION

Mounting evidence reveals NBO can increase the partial pressure of oxygen, attenuate neuron injury, improve oxidative metabolism, and reduce free radical damage. NBO application in cerebral ischemia is a topic of ongoing interest.16-20 The protective effect of NBO is mainly based on freezing ischemic penumbra.12,18,21 CCI is a prolonged state of hypoxic brain tissue, which may mimic the pathogenesis of ischemic penumbra in stroke.1,8 Since NBO yields some benefit to the penumbra, in theory, it has the potential to play an ameliorative effect on CCI as well.9 As many CCI patients have non-focal neurological symptoms (such as headache, dizziness, cognitive decline etc.), rather than focal neurological symptoms and signs, as we all know that the subjective neurological assessments (such as NIHSS, mRS, Barthel index, etc.) may be less useful for immediate real-time NBO therapeutic assessment. On the contrary, EEG can reflect cerebral functional changes sensitively and dynamically.

EEG can reflect the extracellular currents in the dendrites of the cortical pyramidal cells; it is very sensitive for detecting cerebral ischemia and hypoxia.22-25 Brain dysfunction can be represented on EEG through abnormal oscillation of certain frequencies.26-29 Slow-wave background (delta and theta activities) is reported as the most common findings in both acute and sub-acute phases of stroke.30 However, few EEG features have been described for CCI up to now. This study delineated the abnormal EEG oscillations in patients with CCI for the first time and further investigated the efficacy of transient NBO on correcting CCI-mediated EEG anomalies and also preliminary observed the long-term NBO effects in some patients with CCI.

4.1 | The anomalies of EEG in CCI patients

In this study, we found for the first time that the patients with CCI had obvious anomalies on EEG maps when compared with the healthy volunteers, which mainly presented as abnormal high-power oscillations over the forehead electrodes and the paroxysmal slow activity release under the normal-power background. According to this, the abnormal EEG of CCI was divided into the high-power EEG and the normal-power EEG.

Spectral power (AP and RP), which reflects the signal intensity, is generally computed for EEG activity of specific frequencies using FFT.23 The strong association of cerebral blood flow with spectral power has been well acknowledged.25,31,32 Slow background focal delta and theta activities were the most accepted EEG anomalies in cerebral ischemia.23 In this study, the quantitative results were in agreement with the visual evaluation for the raw EEG. The fronto-central AP of each frequency in the high-power EEG was profoundly higher than that in the healthy EEG and the normal-power EEG. Abnormal high voltage and amplitude oscillations enhance the band power; thus, AP could represent the waveform directly. As for the normal-power EEG, the theta and delta RP over the fronto-central electrodes were prominently higher than that in both the healthy EEG and the high-power EEG. The RP mainly reflects the components of the EEG oscillation, which means that more frequent slow activity release can cause higher theta and delta proportions over the whole power. However, the differences of slow frequency RP between the normal-power EEG and the healthy EEG were diminished when adjusting for age and gender. The EEG oscillations in elderly people may slow down gradually,33,34 whereby, whether CCI contributes to the higher RP of slow activities directly in the normal-power EEG should be interpreted modestly.

Notably, the fronto-central TAR, DAR, and DTABR, which represent the ratio of the slow activities to the fast activities, were the highest in the normal-power EEG when compared with the healthy EEG and the high-power EEG, even after adjusting for age and gender. This suggests that CCI could enhance the slow activity release under the normal-power background, the EEG of which was completely different from the healthy EEG and the high-power EEG regardless of age and gender discrepancy. Both the DAR and the DTABR are associated with clinical outcomes such as NIHSS and mRS scores, and they are also deemed as important indices in stroke patients.35-37 This study also corroborated that the DAR and DTABR could represent the clinically relevant features of the normal-power EEG, even superior to theta and delta RP. We calculated the TAR, as a measurement index in this study, as we found that theta accounted for a significant proportion in slow activities under the normal-power EEG. Due to the increment of power over all frequency bands, high-power EEG did not present DAR, DTABR, and TAR elevation. The FOAR, which is the ratio of fronto-central to occipital alpha power, was soundly higher in the high-power EEG, compared with the normal-power and the healthy EEG. Generally, alpha power at the forehead is substantially lower than that at the occipital lobe when people maintaining awake with eyes closed.23 By the comparison of the occipital alpha power, the FOAR could evaluate whether the forehead alpha power was extremely elevated. The results showed that the fronto-central alpha power was definitely increased in the high-power EEG, which corresponded with the AP analysis aforementioned.

The EEG signal complexity had been studied by means of wavelet entropy. Entropy analysis could provide a quantitative measure of the degree of brain injury and recovery.15 The entropy in the high-power EEG was significantly lower than that in the normal-power EEG and the healthy EEG, which indicated that brain injury of the patients with high-power EEG would be more severe than that in the patients with normal-power EEG.
4.2 The immediate effect of NBO on correcting EEG anomalies in CCI patients

In this study, we found that the EEG anomalies could be corrected by NBO immediately for the first time; that is, the high-power oscillations were ameliorated and the paroxysmal slow activity release was controlled. Therefore, we concluded that NBO might improve the brain dysfunctions induced by CCI.

As discussed above, the frequency-band AP and the FOAR may be more appropriate to reflect the high-power condition; the frequency-band RP, and TAR, DAR, and DTABR may represent the paroxysmal slow activities under the normal-power background. Therefore, these parameters were used to evaluate the effect of NBO on EEG anomalies. For the high-power EEG in NBO group, the fronto-central alpha AP and FOAR were significantly reduced, and the AP of the other frequency bands tended to be decreased. In control group, the theta RP and TAR were increased profoundly after resting, which might be caused by drowsiness. The frontal-central AP reduction rates over the four frequency bands in NBO group were statistically higher than those in control group. These results strongly demonstrate that NBO application to the CCI patients with the high-power EEG could ameliorate their abnormal high-power oscillations immediately. As for the normal-power EEG, NBO reduced the fronto-central delta RP, and TAR, DAR, and DTABR significantly meanwhile elevated the alpha RP as well. However, all these parameters did not change in control group after resting. These results unraveled the paroxysmal slow activities release under the normal-power background could be suppressed by NBO remarkably. The wavelet entropy did not change after NBO use. The EEG complexity is associated with brain injury, which cannot be alleviated by short-term NBO.15

4.3 The long-term effect of NBO on correcting EEG anomalies in CCI patients

After long-term NBO use, the patients did not complain of any uncomfortable feelings, which indicated that long-term NBO application to CCI patients was safe. Only five CCI patients with high-power EEG were followed-up, in whom the fronto-central alpha AP and RP were significantly reduced. NBO in these patients could ameliorate the abnormal high-power waveform over a long-term intervention. Only two CCI patients with normal-power EEG were available for follow-up; thus, the long-term EEG outcomes cannot provide a confirmatory result for this cohort.

4.4 Limitations

Firstly, the small sample size may bias the results toward null hypothesis. Especially for the patients with long-term NBO use, the improvement of EEG anomalies may be more obvious after enlarging the sample size. Secondly, the age in healthy volunteers was not well-matched with that in the CCI patients. Healthy controls are too difficult to be found in aged populations due to the high incidence of CCI.1 A larger recruitment may offset this mismatch in the future. However, in general, the voltage and power of oscillations declined gradually with age33,34; thus, the bias from age mismatch in this study tended to negate the actual differences between the CCI and the healthy control. Meanwhile, we also performed multivariate analysis to rule out the confounding impact of age, in order to obtain the more accurate results. Thirdly, despite trying to select EEG epoch with patients maintaining awake and eyes closed, the drowsiness-induced theta activity was inevitable under long periods of sitting/lying, especially when patients rested in room air.

5 CONCLUSION

NBO can rapidly ameliorate CCI-related EEG anomalies, including attenuating the abnormal high-power oscillations and suppressing the paroxysmal slow activities in the CCI condition. Long-term NBO performance may still benefit in the CCI patients to some extent. NBO may be a promising approach to protect the brain from CCI-induced cerebral dysfunctions.

ACKNOWLEDGEMENTS

We would like to thank all patients and doctors who participated in this study for their cooperation.

CONFLICT OF INTEREST

JD, YL, GR, ZC, SZ, YD, XJ, and RM report no conflicts of interest.

AUTHORS’ CONTRIBUTIONS

J.-Y.D., Y.L., and R.M. formulated the conception and design of the study, drafted the manuscript, and prepared the figures; Z.-Y.C., S.-Y.Z., J.-Y.D., and R.M. contributed to data acquisition; Y.L. and S.-Y.Z. recorded the EEG maps; J.-Y.D. and Z.-Y.C. were responsible for the EEG data analysis; G.-B.R. and Y.-C.D. made critical revisions of the manuscript; G.-B.R., Y.-C.D., and X.-M.J. gave the pivotal advices for the study design, data interpretation, and statistical analysis. G.-B.R and Y.-C.D. refined the use of English.

DATA AVAILABILITY STATEMENT

The data presented in the study are available in the supplementary material of this article. Further inquiries can be directed to the corresponding authors.

ORCID

Jia-Yue Ding https://orcid.org/0000-0003-3562-2187
Zhi-Ying Chen https://orcid.org/0000-0001-6020-4484
Xun-Ming Ji https://orcid.org/0000-0003-0293-2744
Ran Meng https://orcid.org/0000-0003-1190-4710

REFERENCES

1. Zhou DA, Meng R, Li SJ, et al. Advances in chronic cerebral circulation insufficiency. CNS Neurosci Ther. 2018;24:5-17.
